<html><head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    </head>
    <body>
    <p style="color:black;font-family: Microsoft YaHei,微软雅黑;font-size:13px;"><br>
    <br>
    Hi ,<br>
    <br>
    Please check germline results of 201103_Novaseq_A00869_B_BHL5MHDSXY_csmart2_0_SPM_v20_86_BJ_auto.
    <br>
    <br>
    共7对样本,4个位点. <br>
    <br>
    Data path: /share/Onc_SmallPanel/capsmart_86gene/201103_Novaseq_A00869_B_BHL5MHDSXY_csmart2_0_SPM_v20_86_BJ_auto<br>
    <br>
    <br>
    ----检测突变审核----<br>
    <br>
    ##可能涉及合并的突变:<br>
    ##P/LP/VUS突变审核：<br>
    Z19W07240-F1WA样品包含Uncertain significance点，NM_007294(BRCA1)：c.3287A&gt;G（p.Q1096R），Postion:chr17:41244261-41244261，Genotype:het,Depth_ref:250,Depth_alt:267,Alt_ratio:0.52，证据为PVS0PS0PM1PP0BA0BS0BP0_pm2。mark信息为clinvar 69487;Popfreq 1000g2015aug_eas . / gnomAD_AF_eas
     . / gnomAD_AF_popmax . / PopFreqMax . ;BZ8K 0.0001;silico 2;,对应解释：<br>
    * BRCA1基因抑癌,(Name:familial breast/ovarian cancer gene 1;Molecular Genetics:Rec;Role in Cancer:TSG;Genome Location:17:41197695-41276113;Chr Band:17q21;Somatic:yes;Germline:yes;Tumour Types(Somatic):ovarian;Tumour Types(Germline):&quot;breast, ovarian&quot;);<br>
    * 突变为nonsynonymous SNV;<br>
    * 人群频率 1000g2015aug_eas：. , gnomAD_AF_eas：. , gnomAD_AF_popmax：. , PopFreqMax：. , BZ8K：0.0001;<br>
    * 根据程序预测综合评分，未达显著，（阈值：pp3&gt;=4 or bp4 &lt;=-4）;<br>
    * ClinVar 数据库收录了该条记录（69487[alleleid] ，0P&#43;0LP&#43;3VUS&#43;0B&#43;0LB/3，CLNSIG=Uncertain significance，CLNREVSTAT=criteria provided, multiple submitters, no conflicts）;<br>
    * Class_Comments: A (A:解读结论和ClinVar一致;B:解读结论和ClinVar的临床意义结论一致;C:结论和Clinvar冲突;N:新增点);<br>
    * 深度信息已通过Atlas软件进行校正;<br>
    --------------------<br>
    Z19N00430-F1WA样品包含Uncertain significance点，NM_007294(BRCA1)：c.3223A&gt;T（p.N1075Y），Postion:chr17:41244325-41244325，Genotype:het,Depth_ref:381,Depth_alt:278,Alt_ratio:0.42，证据为PVS0PS0PM1PP1BA0BS0BP0_pm2pp3。mark信息为Popfreq 1000g2015aug_eas . / gnomAD_AF_eas . / gnomAD_AF_popmax
     . / PopFreqMax . ;silico 4;,对应解释：<br>
    * BRCA1基因抑癌,(Name:familial breast/ovarian cancer gene 1;Molecular Genetics:Rec;Role in Cancer:TSG;Genome Location:17:41197695-41276113;Chr Band:17q21;Somatic:yes;Germline:yes;Tumour Types(Somatic):ovarian;Tumour Types(Germline):&quot;breast, ovarian&quot;);<br>
    * 突变为nonsynonymous SNV;<br>
    * 人群频率 1000g2015aug_eas：. , gnomAD_AF_eas：. , gnomAD_AF_popmax：. , PopFreqMax：. ;<br>
    * 根据程序预测综合评分，判断为有害突变，（阈值：pp3&gt;=4 or bp4 &lt;=-4）;<br>
    * ClinVar 数据库无该条记录;<br>
    * Class_Comments: N (A:解读结论和ClinVar一致;B:解读结论和ClinVar的临床意义结论一致;C:结论和Clinvar冲突;N:新增点);
    <br>
    * 深度信息已通过Atlas软件进行校正;<br>
    - - - - - -<br>
    Range: chr17:41244325-41244325<br>
    Overlapped reads: 843<br>
    G:1 (0.12%) (0&#43;,1-) average quality is 11<br>
    A:338 (40.09%) (179&#43;,159-) average quality is 35<br>
    T:504 (59.79%) (265&#43;,239-) average quality is 35<br>
    --------------------<br>
    <br>
    <br>
    共计审核2个突变位点<br>
    <br>
    <br>
    ====================================<br>
    <br>
    【Somatic Check】: <br>
    <br>
    ----检测突变审核----<br>
    <br>
    ##可能涉及合并的突变:<br>
    ##P/LP/VUS突变审核：<br>
    Z19R00630-b1TA样品包含Likely pathogenic点，NM_002168(IDH2)：c.419G&gt;A（p.R140Q），Postion:chr15:90631934-90631934，Genotype:het,Depth_ref:2525,Depth_alt:67,Alt_ratio:0.03，证据为PVS0PS1PM2PP1BA0BS0BP0_ps1pm1pm2pp3。mark信息为clinvar 29755;Popfreq 1000g2015aug_eas . / gnomAD_AF_eas
     5.437e-05 / gnomAD_AF_popmax 6.155e-05 / PopFreqMax 0.0003 ;silico 9;,对应解释：<br>
    * IDH2基因致癌,(Name:&quot;isocitrate dehydrogenase 2 (NADP&#43;), mitochondrial&quot;;Molecular Genetics:Dom;Role in Cancer:oncogene;Genome Location:15:90627498-90645622;Chr Band:15q26.1;Somatic:yes;Germline:-;Tumour Types(Somatic):glioblastoma;Tumour Types(Germline):-);<br>
    * 突变为nonsynonymous SNV;<br>
    * 人群频率 1000g2015aug_eas：. , gnomAD_AF_eas：5.437e-05 , gnomAD_AF_popmax：6.155e-05 , PopFreqMax：0.0003 ;<br>
    * 根据程序预测综合评分，判断为有害突变，（阈值：pp3&gt;=4 or bp4 &lt;=-4）;<br>
    * ClinVar 数据库收录了该条记录（29755[alleleid] ，6P&#43;1LP&#43;0VUS&#43;0B&#43;0LB/7，CLNSIG=Pathogenic，CLNREVSTAT=Likely pathogenic）;<br>
    * Class_Comments: B (A:解读结论和ClinVar一致;B:解读结论和ClinVar的临床意义结论一致;C:结论和Clinvar冲突;N:新增点);<br>
    --------------------<br>
    Z19W07240-k1TA样品包含Uncertain significance点，NM_021642(FCGR2A)：c.446C&gt;T（p.P149L），Postion:chr1:161479694-161479694，Genotype:het,Depth_ref:579,Depth_alt:571,Alt_ratio:0.50，证据为PVS0PS0PM2PP0BA0BS0BP1_pm1pm2bp4。mark信息为Popfreq 1000g2015aug_eas . / gnomAD_AF_eas . /
     gnomAD_AF_popmax . / PopFreqMax . ;silico -7;,对应解释：<br>
    * 突变为nonsynonymous SNV;<br>
    * 人群频率 1000g2015aug_eas：. , gnomAD_AF_eas：. , gnomAD_AF_popmax：. , PopFreqMax：. ;<br>
    * 根据程序预测综合评分，判断为无害突变，（阈值：pp3&gt;=4 or bp4 &lt;=-4）;<br>
    * ClinVar 数据库无该条记录;<br>
    * Class_Comments: N (A:解读结论和ClinVar一致;B:解读结论和ClinVar的临床意义结论一致;C:结论和Clinvar冲突;N:新增点);
    <br>
    --------------------<br>
    <br>
    <br>
    共计审核2个突变位点<br>
    </p>
    <div style="font-size:9pt;  font-family: 'Calibri',sans-serif;"></div>
    &nbsp;<br>
    <table>
    <tbody>
    <tr>
    <td rowspan="1"><img alt="Berrygenomics" src="http://www.berrygenomics.com/repository/image/eb50ea8f-
    
    239d-4939-a331-65c2f5fd0db7.jpg_366xaf.jpg"></td>
    <td style="vertical-align: bottom"><span style="font-size:11pt;font-weight:bold;  font-family: '微软雅黑','times new 
    
    roman','garamond',serif;">肿瘤突变复核 |
    </span><br>
    <span style="font-size:10pt;  font-family: '微软雅黑','times new 
    
    roman','garamond',serif;color:#7F7F7F">福建和瑞基因科技有限公司<br>
    <span style="font-weight:bold;">电话：</span><br>
    <span style="font-weight:bold;">邮箱：</span>oncology_mut_review@berryoncology.com<br>
    <span style="font-weight:bold;">官网：</span><a href="http://www.berryoncology.com">www.berryoncology.com</a><br>
    <span style="font-weight:bold;">地址：</span><br>
    </span></td>
    </tr>
    </tbody>
    </table>
    <img alt="Berrygenomics" src="http://www.berrygenomics.com/repository/image/e8eecbf6-c80b-4968-bfdf-
    
    38f75b3b6c0d.jpg_366xaf.jpg"><br>
    <span style="font-size:8pt;  font-family: '微软雅黑','times new roman','garamond',serif;">本电邮所包含或其随附的信息可能属于保密信息，仅供指定收件方使用。如阁下并非本电邮指明的收件方，请将阁下拥有的本电邮 及其所有备份（包括所有附件）删除并销毁，并将阁下误收本电邮一事通知发件方；在此特提请阁下注意不得泄露、复制或散发本电邮，并 不得倚赖本电邮而采取任何行动。The information contained in and accompanying
     this email may be confidential, and is intended solely for the use of the intended recipient(s). If you are not the intended recipient of this email, please delete and destroy all copies (including any attachments) in your possession, notify the sender that
     you have received this email in error, and you are hereby notified that any disclosure, duplication or dissemination of, or the taking of any action in reliance on this email is expressly prohibited.
    </span>
    </body>
    </html>
    